- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03911739
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (MOMs-INO)
NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): Infant Neurodevelopmental Outcomes (INO) Sub-study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Frankie Kropp, MS
- Phone Number: 513-585-8290
- Email: kroppfb@ucmail.uc.edu
Study Contact Backup
- Name: Ben Kropp, MSLS
- Phone Number: 513-585-8287
- Email: kroppbn@ucmail.uc.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Withdrawn
- Zuckerberg San Francisco General
-
-
Florida
-
Jacksonville, Florida, United States, 32204
- Recruiting
- Gateway Community Services
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Recruiting
- Boston Medical Center
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital HOPE Clinic
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- Withdrawn
- University of New Mexico Milagro Clinic
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Withdrawn
- University of Cincinnati Health Perinatal Addictions Program
-
-
Oregon
-
Portland, Oregon, United States, 97214
- Completed
- CODA, Inc.
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- Pregnancy Recovery Center at Magee-Womens Hospital of UPMC
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University Medical Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Recruiting
- University of Utah SUPeRAD Clinic
-
-
Washington
-
Seattle, Washington, United States, 98107
- Active, not recruiting
- Addiction Recovery Services (ARS), Swedish Medical Center
-
-
West Virginia
-
Huntington, West Virginia, United States, 25701
- Recruiting
- Marshall Health MARC Program
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The participant must be the caretaker of an infant that was delivered as part of the MOMs trial (Unique protocol ID: 2019-0429-1).
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BUP-XR
Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly. The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.). |
Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
Other Names:
|
Active Comparator: BUP-SL
Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase. The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.). |
Sublingual buprenorphine (BUP-SL), administered daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bayley Scales of Infant Development
Time Frame: 24 months post-partum
|
The Bayley Scales of Infant Development is considered the gold standard assessment of early child development and includes cognitive, language, fine motor, and gross motor subscales.
Subscale scores each range from 1 - 19, with higher scores indicating higher performance.
|
24 months post-partum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bayley Scales of Infant Development
Time Frame: 12 months post-partum
|
The Bayley Scales of Infant Development is considered the gold standard assessment of early child development and includes cognitive, language, fine motor, and gross motor subscales.
Subscale scores each range from 1 - 19, with higher scores indicating higher performance.
|
12 months post-partum
|
Child Behavior Checklist
Time Frame: 24 months post-partum
|
The Child Behavior Checklist includes items that describe behavioral, emotional, and social problems that characterize preschool children.
|
24 months post-partum
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: T. John Winhusen, PhD, University of Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Disease
- Infant, Newborn, Diseases
- Narcotic-Related Disorders
- Substance-Related Disorders
- Syndrome
- Opioid-Related Disorders
- Substance Withdrawal Syndrome
- Neonatal Abstinence Syndrome
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Buprenorphine
Other Study ID Numbers
- 2019-0429-3
- UG1DA013732 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy Related
-
Helen Keller InternationalEleanor Crook FoundationNot yet recruitingPregnancy Related | Supplementation | Postnatal Related
-
4YouandMeCambridge Cognition Ltd; Sema4; Evidation Health; Vector Institute of Artificial... and other collaboratorsCompletedPregnancy Related | Wearables | Pregnancy EarlyUnited States
-
The University of Texas Health Science Center,...CompletedPregnancy Related | Pregnancy, High RiskUnited States
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Shaare Zedek Medical CenterUnknownPregnancy Related | Pregnancy, High Risk | Anesthesia
-
Ataturk UniversityNot yet recruiting
-
Medical College of WisconsinNot yet recruiting
-
University of PennsylvaniaNot yet recruiting
-
Centre for Infectious Disease Research in ZambiaWellcome Trust; Neopenda, PBCRecruiting
-
Emory UniversityNational Institute of Nursing Research (NINR)Recruiting
Clinical Trials on Buprenorphine Injection
-
T. John Winhusen, PhDNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCActive, not recruitingPregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal SyndromeUnited States
-
Madhukar H. Trivedi, MDTerminatedMethamphetamine-dependenceUnited States
-
T. John Winhusen, PhDNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCActive, not recruitingPregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal SyndromeUnited States
-
University of PennsylvaniaRecruitingOpioid Use DisorderUnited States
-
New York State Psychiatric InstituteCompletedOpioid-use DisorderUnited States
-
Braeburn PharmaceuticalsCompletedOpioid Use DisordersUnited States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)Withdrawn
-
Indivior Inc.CompletedOpioid Use DisorderUnited States
-
Montefiore Medical CenterRecruiting
-
Steve N. Caritis, MDEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingPregnancy | Opiate AddictionUnited States